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Hunter’s disease or mucopolysaccharidosis (MPS II) is a hereditary metabolic disorder manifesting almost exclusively in males caused by deficiency of iduronate-
2-sulfatase (IDS) enzyme whose gene is mapped to Xq 28 [1]. 
It was first described by Hunter, in 1917 [2]. The common 
clinical features include facial dysmorphism, joint stiffness, 
contractures, hepatosplenomegaly, pulmonary dysfunction, 
valvular dysfunction, cardiomyopathies, and neurological 
involvement [3]. Care of MPS II is predominantly palliative, 
as there is no effective therapy for the same. However, enzyme 
replacement therapy (ERT) with recombinant human iduronate-
2-sulfatase has now been introduced. We report this case to 
highlight the physical perspective and mental subnormality in a 
child with Hunter’s disease.
CASE REPORT
A 10-year-old boy born to a non-consanguineous marriage 
presented with complaints of growth retardation and joint stiffness 
with progressive restriction of movements in hands and legs for 
past 6 years (Fig. 1). The child was apparently well till 3 years of 
age when mother noticed abdomen distension which was gradual 
and associated with intermittent diarrhea and breathing difficulty 
which used to increase in lying down posture. There was no history 
of pain in abdomen and bladder alterations. He had a history of 
recurrent cough, cold, and decreased hearing for past 5 years with 
associated speech delay. He had delayed milestones and impaired 
adaptive functioning. There was no history of trauma and any 
deformity in back/spine. His birth history was unremarkable.
On examination, the child was conscious, afebrile, and 
well oriented with stable vitals. He was underweight and short 
stature, had coarse facies, macroglossia, prominent frontal bulge, 
depressed nasal bridge, short neck, and short fingers with flexion 
of distal interphalangeal joint (Fig. 2). He had limitation of 
extension at knee, ankle (Fig. 3), elbow, and wrist joints (Fig. 2). 
Mild abdomen distension with umbilical herniation (Fig. 1) was 
noted. Cardiovascular system examination was normal except an 
ejection systolic murmur in aortic area. His abdomen was soft 
with firm liver, which was 5 cm below the right costal margin 
in the midclavicular line having span of 8 cm; spleen was 1 cm 
below the left costal margin in midclavicular line. Respiratory 
examination was normal.
His investigations including complete hemogram, serum 
calcium, phosphorus, liver and renal function tests, thyroid, 
and lipid profile were normal. X-ray of limbs showed delayed 
appearance of carpal bones with bullet-shaped phalanges and 
V-shaped epiphysis of long bones (Fig. 4). Echocardiography 
revealed mild aortic regurgitation with thickening of valves and 
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moderate mitral regurgitation. Head imaging was suggestive of 
inherited metabolic disorder (Fig. 5). The pure tone audiometry 
detected moderate sensorineural hearing loss. Ophthalmological 
examination was normal. Assessment of intellectual functioning 
revealed an intelligence quotient (IQ) of 50–55.
On the basis of clinical findings and radiological examination, 
probable diagnosis of MPS was made and we decided to perform 
enzyme assay which showed deficiency of IDS, thus confirming 
our diagnosis. Counseling of the parents was done and the 
management options were explained including bone marrow 
transplant. Other supportive management such as physiotherapy 
to mobilize the joint and hearing aid was advised.
DISCUSSION
Hunter’s disease is an X-linked recessive condition; it is not 
expected in females. Despite this, a few cases are reported in 
girls [4]. Conventionally, MPS II was classified into mild and 
severe. Wraith et al. classified it as severe and attenuated [5]. 
Our patient was male who appeared normal at birth; this is the 
classical presentation of Hunter’s disease. The severe form 
manifests at early age between 18 months and 4 years and has 
life expectancy of 10–15 years while mild form manifests in the 
second decade with a life expectancy of 30–50 years [1,6,7]. The 
symptoms in our case manifested in early life, denoting it to be 
of severe subtype having a poor life expectancy. Patients with 
severe form have mental retardation with loss of skills, which 
was seen in our patient and while those of milder form may have 
mild mental retardation, but their intelligence usually is normal. 
Death in both the forms usually occurs due to cardiac failure or 
obstructive airway disease.
The patient of MPS II is short with coarse facial features. 
Thickening of the alae nasi, lips, ear lobules, and tongue becomes 
progressively more obvious. Significant arthropathy leads to joint 
contractures and skeletal defects. A combination of hepatomegaly 
and lax abdominal muscles leads to abdominal distension. Other 
features include pulmonary dysfunction, cardiomyopathies, and 
neuropsychiatric manifestations. Facial and body hypertrichosis 
are often seen and the scalp hair becomes coarse [8]. Much of the 
physical features mentioned above were evident in our patient in 
the form of growth retardation with short stature, coarse facies, 
macroglossia, prominent frontal bulge, depressed nasal bridge, 
Figure 1: Growth retardation and joint stiffness
Figure 2: Coarse facies, short neck, broad nose, flexion of distal 
interphalangeal joint and limitation of extension of elbow joint
Figure 3: Limitation of extension of knee and ankle joint
Figure 4: Radiograph of limbs showing bullet shaped phalanges, V 
shaped epiphysis of long bones and deayed appearance of carpal 
bones
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short neck, short broad and stubby fingers with joint contractures, 
hepatosplenomegaly with umbilical hernia, cardiac defect with 
mental retardation, speech abnormality, and hearing deficit.
MPS II patients are normal at birth and early developmental 
milestones may also be normal, even in the presence of 
significant somatic disease. Our case had normal birth history, 
but manifestations occurred during early childhood with 
speech abnormality, hearing deficit, and intellectual disability, 
radioimaging of head was remarkable for paucity of white 
matter with prominence of ventricles with hypodensities (Fig. 5). 
Communicating hydrocephalus, common in MPS I, is rare in 
MPS II.
The prevalence and severity of cardiovascular disease in MPS 
is 60–100% [9]. It includes incompetence of the valves, mitral 
valve prolapse, ischemic heart disease, and cardiomegaly resulting 
in heart failure [1,6,7]. Orthopedic complications because of 
direct bone involvement and severe arthropathy can lead to 
significant disability. The role of physical therapy in MPS II is not 
well studied, but range of motion exercises offer some benefit in 
preserving joint function and should be started at an early age. If 
significant joint movement restriction has already occurred, range 
of motion exercises may slow further progression [10]. As seen 
in our patient, chronic recurrent rhinitis and persistent copious 
nasal discharge are common in these patients. In severe MPS II, 
rhinorrhea tends to improve with age, but upper airway obstruction 
and sleep apnea become more troublesome as the age progresses. 
Sleep studies should form part of the regular assessment plan and 
significant episodes of hypoxia should be managed by continuous 
or bilevel positive airway pressure devices. Early placement of 
ventilating tubes is recommended in severe forms [10].
As in our patient, MPS II cases are prone to bouts of watery 
diarrhea, which are not associated with malabsorption. Diarrhea 
can be controlled by diet and the use of antimotility drugs [10]. 
Rectal biopsies have demonstrated storage within gut neural 
cells [11]. With age, loss of muscle strength and physical inactivity 
lead to constipation.
The screening test is analysis of glycosaminoglycans. The 
presence of excess heparan and dermatan sulfates in the urine 
is suggestive of MPS I, II, and VII. Confirmatory diagnosis is 
made by enzyme assay, using substrates specific for iduronate-2-
sulfatase. Absent or low iduronate-2-sulfatase activity in males is 
diagnostic of Hunter syndrome [1].
Approved treatment is ERT using a recombinant human 
iduronate-2-sulfatase produced in the human cell line [12], and 
the definitive treatments are bone marrow transplantation and 
umbilical cord blood transplantation. However, these definitive 
treatments are not readily available in most of the developing 
countries, and supportive management is mainstay of therapy 
to improve the quality of life such as physiotherapy to mobilize 
the joints, nutritional management, and treatment of infections, 
blood transfusion, and management of cardiac and respiratory 
complications [13].
A comprehensive initial assessment of patient at diagnosis 
should, therefore, be undertaken and should be followed 
regularly. As far as physical perspective is concerned, supportive 
management and the anticipation of possible complications can 
greatly improve the quality of life. Mental subnormality is a 
very common feature in Hunter syndrome. Progressive cognitive 
decline is not amenable to the ERT due to the non-penetrance of 
blood–brain barrier to the large protein molecules. Thus, even on 
training, a good quality of life might not be achieved. The families 
of this patient need considerable motivation, psychological, and 
social support. They should be offered genetic counseling and 
contact with other affected families, patients, and support groups. 
Hence, it is the role of clinician to provide a good quality of life, 
to counsel them for regular IQ assessment, and to make them 
aware about the future prospects of these patients.
CONCLUSION
Hunter’s disease is a multisystemic disease with constellation 
of physical findings. Its definitive treatment is not available but 
multidisciplinary and a holistic approach, especially for those who 
have severe neurological involvement can improve the quality of 
life. Central nervous system disease remains a major challenge, 
and an innovative approach to treatment with regular evaluation 
of IQ is needed to assess the comorbidities. The child with MPS 
II should be provided a stimulating environment to encourage as 
much learning as possible during the early stages, as some skills 
may be retained during the later period of general deterioration.
REFERENCES
1. Kliegman RM, Behrman RE, Jenson HB, Stanton FB. Nelson Textbook of 
Pediatrics. 20th ed. Philadelphia, PA: Saunders; 2016. p. 737-41.
2. Hunter C. A rare disease in two brothers. Proc R Soc Med 1917;10:104-6.
3. Shah SG, Mahal T, Sharma S. Atypical clinical presentation of 
mucopolysaccharidosis Type II (Hunter syndrome): A case report. J Med 
Figure 5: Neuroimaging of head showing paucity of white matter 
with prominence of ventricle and hypodensities
Vol 5 | Issue 6 | June 2018 Indian J Child Health 456
Wani et al. Hunter’s disease - Its presentation and sequelae
Case Rep 2010;4:154.
4. Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA. Mucopolysaccharidosis 
Type II in females: Case report and review of literature. Pediatr Neurol 
2005;32:270-2.
5. Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J. Initial 
report from the hunter outcome survey. Genet Med 2008;10:e508-16.
6. Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Mufioz V, et al. 
Recognition and diagnosis of mucopolysaccharidosis II (hunter syndrome). 
Pediatrics 2008;121:377-86.
7.	 Tylki-Szymańska	 A.	 Mucopolysaccharidosis	 type	 II,	 hunter’s	 syndrome.	
Pediatr Endocrinol Rev 2014;12 Suppl 1:107-13.
8. Thappa DM, Singh A, Jaisankar TJ, Rao R, Ratnakar C. Pebbling of the 
skin: A marker of hunter’s syndrome. Pediatr Dermatol 1998;15:e370-3.
9. Fesslova V, Corti P, Sersale G, Rovelli A, Russo P, Mannarino S, et al. The 
natural course and the impact of therapies of cardiac involvement in the 
mucopolysaccharidoses. Cardiol Young 2009;19:e170-8.
10. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. 
Mucopolysaccharidosis Type II (Hunter syndrome): A clinical review and 
recommendations for treatment in the era of enzyme replacement therapy. 
Eur J Pediatr 2008;167:267-77.
11. Elsner B. Ultrastructure of the rectal wall in hunter’s syndrome. 
Gastroenterology 1970;58:856-62.
12. Muenzer J, Bodamer O, Burton B, Clarke L, Frenking GS, Giugliani R, 
et al. The role of enzyme replacement therapy in severe hunter syndrome-an 
expert panel consensus. Eur J Pediatr 2012;171:181-8.
13. Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, 
et al. Multidisciplinary management of hunter syndrome. Pediatrics 
2009;124:e1228-39.
Funding: None; Conflict of Interest: None Stated.
How to cite this article: Wani GI, Imran A, Rathore V, Gupta A. Physical 
health perspective and mental subnormality of a child with Hunter’s disease. 
Indian J Child Health. 2018; 5(6):453-456.
